Skip to content

The Predictive Value of Biomakers to Chemotherapy Susceptibility and to Investigate the role of Biomakers in Evaluating therapeutic response of Radiochemotherapy and Prognosis in Cervical Carcinom

The Predictive Value of Biomakers to Chemotherapy Susceptibility and to Investigate the role of Biomakers in Evaluating therapeutic response of Radiochemotherapy and Prognosis in Cervical Carcinom

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONN-16008893
Enrollment
Unknown
Registered
2016-07-23
Start date
2016-07-26
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Carcinom

Interventions

fuor:Biomaker

Sponsors

Guizhou Province Cancer Hospital Affiliated to Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients with histologically cervical biopsy confirmed cervical cancer before treatment and has been in immunohistochemistry, which items to include HIF-1 alpha, CD44v6, COX-2, EGFR; 2. After more than two obstetrics and gynecology gynecological examinations and definiting diagnosis and FIGO stage, and there is a measurable tumor lesions; 3. Before entering the experiment, patients were not treated with radiotherapy, chemotherapy and surgery; 4. Karnofsky score =70 points; 5. Women aged 18 to 70 years; 6. Normal bone marrow function (WBC> 4.0×10^9/L, PLT=100×10^9/L, Hbt>70g/L); 7. Liver function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) <upper limit of normal (ULN) of 1.5 times; total bilirubin <1.5×ULN; renal function: serum creatinine <1.5×ULN; 8. There is no major organ dysfunction, no serious complications, such as hypertension, diabetes, coronary heart disease and a history of mental illness; 9. This study could be understood and the informed consent could be signed.

Exclusion criteria

Exclusion criteria: 1. patients were treated with radiotherapy, chemotherapy and surgery.; 2. Karnofsky score <70 points; 3. Severe lung or heart disease history, activity of systemic infection, drug abuse or alcohol addiction; 4. Creatinine clearance <30ml / min; 5. After entering the experiment, patients receive chronic systemic immunotherapy or hormone therapy; 6. Pregnancy (via the urine or serum ß-HCG test confirmed) or during lactation; 7. Researchers comfirm that patient has a physical or mental illness, which causes the patient was unable to fully understand the possible complications in this study. And patient with or without civil capacity or with limited capacity for civil conduct.

Design outcomes

Primary

MeasureTime frame
short-term curative effect;

Countries

China

Contacts

Public ContactJiehui Li

Guizhou Medical University

512111848@qq.com+86 15185191569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026